10-K: Merit Medical Systems Reports Strong 2024 Results, Driven by Strategic Acquisitions and Global Growth

Merit Medical Systems, Inc. announces a successful fiscal year 2024, marked by significant revenue growth, strategic acquisitions, and advancements in key product areas.

Summary

• Merit Medical Systems, Inc. reported net sales of $1.357 billion for the year ended December 31, 2024, an increase of 7.9% compared to 2023.
• The company's revenue growth was primarily driven by demand in the U.S. and favorable international sales trends, particularly in EMEA and ROW regions.
• Gross profit as a percentage of sales increased to 47.4% in 2024 from 46.4% in 2023.
• Net income for 2024 was $120.4 million, or $2.03 per share, compared to $94.4 million, or $1.62 per share, in 2023.
• Merit Medical completed the acquisitions of EndoGastric Solutions, Inc. and a portfolio of Lead Management products from Cook Medical in 2024.
• The company introduced its Continued Growth Initiatives Program with multi-year financial targets for the three-year period ending December 31, 2026.
• The Wrapsody Cell-Impermeable Endoprosthesis received premarket approval from the FDA in December 2024.
• U.S. sales accounted for 59% of net sales, while international sales grew 4.8% and accounted for 41% of net sales.
• China represented 11% of net sales in 2024, with sales of $149.8 million.
• The company expects to continue to experience negative impacts from China's volume-based procurement (VBP) policy in 2025.
• Research and development expenses increased by 5.7% to $87.5 million in 2024.
• The company had cash, cash equivalents, and restricted cash of $378.8 million as of December 31, 2024.
• The company anticipates spending approximately $55 to $60 million in 2025 for property and equipment.
• The company has outstanding borrowings of $747.5 million under the Convertible Notes and the Amended Fourth A&R Credit Agreement as of December 31, 2024.
• A committee of independent directors is overseeing a succession plan in preparation for the retirement of Fred P. Lampropoulos, anticipated around December 31, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, strategic acquisitions, and new product approvals. However, it also acknowledges certain risks and challenges, such as the impact of China's VBP policy and regulatory compliance requirements.

Positives

• Strong revenue growth of 7.9% in 2024, indicating increasing market demand for Merit Medical's products.
• Improved gross profit margin, reflecting enhanced operational efficiency and product mix.
• Significant increase in net income, demonstrating improved profitability.
• Successful completion of strategic acquisitions, expanding the company's product portfolio and market reach.
• FDA approval of the Wrapsody Device, opening up new revenue opportunities in the U.S.
• Launch of the Continued Growth Initiatives Program, signaling a commitment to long-term sustainable growth.
• Increased U.S. sales, driven primarily by the U.S. direct, OEM and endoscopy businesses.

Negatives

• Continued negative impacts expected from China's volume-based procurement (VBP) policy in 2025, potentially affecting revenue in a key international market.
• The company is operating under a Corporate Integrity Agreement with the OIG, requiring significant resources and management attention.
• The company is subject to evolving domestic and foreign laws and regulations regarding privacy and data protection.
• The company is routinely a party to litigation, which could affect our financial condition and results of operations.

Risks

• Disruptions in the supply chain from third-party vendors could adversely affect the business.
• Changes in economic and geopolitical conditions may negatively impact the company's financial performance.
• Consolidation in the healthcare industry and cost-containment measures may lead to demands for price concessions.
• The company may be unable to compete in its markets due to technological changes or new market entrants.
• The company may be unable to successfully manage growth through acquisitions.
• Failure to realize the benefits expected from recent acquisitions could adversely affect the business.
• The FDA regulatory clearance process is extensive and dynamic, and failure to obtain and maintain required regulatory clearances and approvals could prevent the company from commercializing its products.
• The company is subject to laws targeting fraud and abuse in the healthcare industry.
• Limits on reimbursement imposed by governmental and other programs may adversely affect the business.
• The company may not be able to protect its intellectual property.
• The company relies on the proper function, availability and security of information technology systems to operate its business, and a material disruption of critical information systems or a material breach in the security of our systems may adversely affect our business, reputation and financial condition.
• The agreements and instruments governing the company's debt contain restrictions and limitations that could significantly affect its ability to operate its business, as well as significantly affect its liquidity.
• The market price of the company's common stock has been and may continue to be volatile.
• Fluctuations in foreign currency exchange rates may negatively impact the company's financial results.
• The company's business and operations are subject to risks related to climate change.
• The company could be negatively impacted by corporate social responsibility laws, regulations, practices and expectations.

Future Outlook

Merit Medical is committed to better-positioning itself for long-term, sustainable growth and enhanced profitability through its Continued Growth Initiatives Program. The company anticipates spending approximately $55 to $60 million in 2025 for property and equipment. The company expects that the VBP tender process in China will continue to have a negative impact on the revenue it is able to generate in China in 2025.

Industry Context

Merit Medical operates in the complex, highly competitive and challenging global medical technology marketplace, specifically in the areas of cardiology, radiology, oncology, critical care and endoscopy. This marketplace is characterized by rapid technological advancement, industry and customer consolidation, customer demands for price reductions, regulatory reform, and evolving patient needs.

Comparison to Industry Standards

• Merit's primary competitors in the peripheral intervention market include Teleflex Incorporated, Cook Medical Incorporated, Medtronic plc, Boston Scientific Corporation, and Becton, Dickinson and Company.
• In the cardiac intervention market, Merit competes with BD, Teleflex, Medtronic, Abbott Laboratories, Terumo Corporation, Edwards Lifesciences Corporation, Cook Medical, and Boston Scientific.
• Key competitors in the spine market are Medtronic, Stryker Corporation, and Johnson & Johnson.
• Merit's oncology market competitors include BD, Hologic, Inc., Endomagnetics Ltd., Argon Medical Devices, Inc. and Cook Medical.
• The endoscopy market sees competition from Getinge AB, Boston Scientific, Cook Medical, and Olympus Corporation.
• Merit believes it is a leading provider of digital inflation technology globally and a market leader in the U.S. for analog inflation devices, control syringes, radar localization, waste-disposal systems, embolic beads, tubing and manifolds.

Legal Proceedings

• The company is cooperating with a SEC inquiry regarding the business activities of Merit's subsidiary in China.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue, profitability, and strategic growth initiatives.
• Employees: Potential for positive impact through career development and engagement programs, but also potential uncertainty due to restructuring and management changes.
• Customers: Potential for improved product offerings and customer service through acquisitions and new product development.
• Suppliers: Potential for increased business opportunities through the company's growth and expansion.

Next Steps

• Commercialization of the Wrapsody Device in the U.S. in 2025.
• Continued implementation of the Continued Growth Initiatives Program.
• Continued efforts to comply with regulatory requirements, including MDR in Europe.
• Continued monitoring of the impact of China's VBP policy.
• Implementation of a global performance management program in 2025.

Key Dates